Key facts
- It has raised $18.8M; the latest was Later Stage VC ($9.6M) in Jul 2024.
- Notable investors include Innovate UK, AlbionVC, Albion Capital, Catapult Ventures, Kings Arms Yard VCT — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Proveca
- ·The full record, as it builds
Funding rounds
No funding rounds for Proveca are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Proveca
Operator of a pharmaceutical company intended to specialize in the development and licensing of medicines to address unmet medical needs in children. The company focuses on curing medical issues related to neurology, cardiology, and analgesia in children, enabling doctors to access the medication for children in an appropriate format and per requirements.
- Sector
- Healthcare
- HQ
- Manchester, United Kingdom
- Founded
- 2010
- Employees
- 65
- Website
- proveca.com/
- Ownership
- Privately Held (backing)
Proveca doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Proveca shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Proveca in its N-PORT filings yet. We sweep new filings monthly.